|
pubmed:abstractText |
Second generation antipsychotics (SGA) have demonstrated several advantages over first generation antipsychotics (FGA) in terms of positive, negative, cognitive, and affective symptoms and a lower propensity for extrapyramidal side effects. Despite these undeniable advantages, SGA have been associated with causing and exacerbating metabolic disorders, such as obesity, diabetes, and hyperlipidemia. This cross sectional study aimed to evaluate the metabolic risk factor profile associated with use of SGAs in comparison with non -treated control patients.
|
|
pubmed:affiliation |
Institute of Psychiatry, Bologna University, Viale C, Pepoli 5, 40123 Bologna, Italy. ilariata@alma.unibo.it
|
